Results 101 to 110 of about 1,518,868 (239)

Exploring the current potential of immunotherapeutic-based treatment approaches for the management of oral cancer: An updated review

Oral Oncology Reports
One of the most prevalent cancers of the head and neck, oral cancer may seriously hinder eating, represent a danger to life, and impair appearance. The three primary clinical therapies for oral cancer are chemotherapy, radiation, and surgery.
Abin V. Geevarghese, R. Gopika
doaj   +1 more source

In Vivo Direct Reprogramming: Current Progress and Future Prospects from Mechanisms to Therapeutic Application

Advanced Science, EarlyView.
This review examines the potential of in vivo direct reprogramming in regenerative medicine for functional tissue restoration, highlighting the role of tissue‐resident cues in generating functionally mature reprogrammed cells from lineage‐related cells. It contains a discussion on mechanisms, reprogramming factors, delivery approaches, and applications
Rishabh Deo Singh, Mauro Calvoli, Kyeong Kyu Kim   +2 more
wiley   +1 more source

Real-world safety and effectiveness analysis of low-dose preschool sesame oral immunotherapy

Journal of Allergy and Clinical Immunology: Global
Background: Previous studies support the effectiveness of sesame oral immunotherapy (S-OIT) in patients >4 years old using maintenance doses of 1200 mg protein.
Gilbert T. Chua, MBBS, Lianne Soller, PhD, Sandeep Kapur, MD, Mary McHenry, MD, Gregory A. Rex, MD, Victoria E. Cook, MSc, MD, Scott B. Cameron, MD, PhD, Edmond S. Chan, MD, Joanne Yeung, MD, Stephanie C. Erdle, MD   +9 more
doaj   +1 more source

The current state of food allergy therapeutics

Human Vaccines & Immunotherapeutics, 2017
The prevalence of IgE mediated food allergy is an increasing public health concern. The current standard of treatment is strict avoidance of the offending food(s). There are no FDA approved treatments for food allergy.
Meng Chen, Michael Land
doaj   +1 more source

GSTM4 Suppresses Prostate Cancer Progression by Targeting TRIM27‐mediated ACLY Ubiquitination and Lipid Metabolism

Advanced Science, EarlyView.
GSTM4 enhances the interaction between ACLY and the E3 ubiquitin ligase TRIM27, thereby increasing K48‐linked ubiquitination at the K554 site of ACLY and promoting its degradation. Consequently, GSTM4 regulates lipid synthesis, as well as the proliferation and metastasis of PCa cells, by modulating ACLY stability.
Kang‐Ping Xiong, Fei Liu, Wang Wang, Gang Wang, Kai‐Yu Qian, Sheng Tu, Si‐Ming Chen, Hui‐Min Xu, Shan‐Shan Zhang, Yong Li, Xing‐Huan Wang, Hong Weng   +11 more
wiley   +1 more source

Oral immunotherapy for cow’s milk allergy in children: a systematic review and meta-analysis

Frontiers in Immunology
ObjectiveCow’s milk allergy (CMA) is one of the most common causes of food allergies (FA) in children. There have been studies on the use of immunotherapy in cow’s milk protein allergy, with oral immunotherapy (OIT) being the most extensively researched.
Yan Wang, Yan Wang, Shunli Liu, Shunli Liu, Meizhu Lu, Meizhu Lu, Jingyu Guo, Jingyu Guo, Can Lv, Can Lv, Lan Huang, Lan Huang   +11 more
doaj   +1 more source

Chemotherapy‐Activated GSK3β‐DNMT1 Signaling Upregulates CD47 to Evade Macrophage Phagocytosis and Drive Temozolomide Resistance in Glioblastoma

Advanced Science, EarlyView.
Temozolomide treatment activates GSK3β, driving DNMT1 phosphorylation, destabilization, and CD47 promoter hypomethylation in glioblastoma. This epigenetic shift upregulates CD47, enabling TMZ‐treated GBM cells to evade macrophage phagocytosis, survive chemotherapy, and acquire resistance.
Jie Li, Shuai Ying, Yi Zhang, Jingjing Wang, Quan Wan, Lingli Gong, Daxing Xu, Zhenkun Yang, Hongnian Lu, Ying Yin, Xiangming Fang, Zhening Pu   +11 more
wiley   +1 more source

Trends in allergen-reactive CRTH2+ T cells and TARC associated with successful outcomes in a phase 2 cashew oral immunotherapy study

Frontiers in Immunology
BackgroundWe designed an oral immunotherapy (OIT) clinical trial for cashew allergy to further our understanding of immunological responses with treatment, including changes in allergen-specific T cells.
Sayantani B. Sindher, Andrea Fernandes, Monali Manohar, Shu Cao, Sheena Gupta, Sheena Gupta, Ella Parsons, Dinara Bogetic, Divya Kumar, Jessica Rogers, Julia Thompson, Diane Dunham, Evan Do, Sofia Maysel-Auslender, Taryn Audrey Liu, Kristine Martinez, Brent Anderson, Abhinav Kaushik, Manisha Desai, Holden Maecker, Holden Maecker, Susan Perry, Lisa M. Wheatley, Kari C. Nadeau, Kari C. Nadeau, R. Sharon Chinthrajah   +25 more
doaj   +1 more source

YTHDC1 Orchestrates Glucose and Glutamate Rewiring to Overcome Lethal Metabolic Stress in Triple‐Negative Breast Cancer

Advanced Science, EarlyView.
Lai et al. find that m6A reader YTHDC1 is specifically overexpressed in triple‐negative breast cancer (TNBC) and orchestrates glucose and glutamine metabolism in an m6A‐dependent manner to confer robust adaptability to lethal metabolic stress. Leveraging YTHDC1 knockdown‐induced metabolic vulnerability, an ATF4 mRNA‐targeted nanotherapy is developed to
Zheng‐Hao Lai, Yi Wang, Na‐Na Li, Ling Zeng, Renzhong Liu, Xue Li, Cheukfai Li, Xin‐Yu Ma, Wenkui Fu, Yingsen Tang, Jinjin Chen, Ning Liao, Man‐Li Luo   +12 more
wiley   +1 more source

Advances in omalizumab treatment for IgE-mediated food allergies

Zhongguo Linchuang Yixue
The increasing prevalence of food allergies significantly affects both the physical and mental health of patients, while concurrently imposing a substantial economic burden on a global scale.
Siqi WANG, Ling YE, Meiling JIN
doaj   +1 more source